New York, NY - Oova, a groundbreaking fertility translator, has successfully raised $10.3 million in a Series A funding round. The investment comes from renowned industry leaders including Samsung Next, US Fertility, Connecticut Innovations, and Spero Ventures, highlighting the immense potential and confidence in Oova's disruptive approach. The funding will be utilized to further enhance Oova's technological capabilities and expand its market presence.

Oova is at the forefront of the biotechnology industry, revolutionizing the way women and their care teams understand and navigate fertility. The company, headquartered in New York, NY, has established itself as a consumer-centric organization that leverages data-driven insights to provide comprehensive fertility information to both patients and healthcare providers.

Oova's pioneering at-home urine test enables women to gain deep insights into their fertility by measuring luteinizing hormone and progesterone levels. This invaluable data allows women to determine their most fertile days and accurately confirm ovulation, empowering them with the knowledge needed to optimize their chances of conception. By delivering advanced personalized analytics and real-time action plans for every hormone reading, Oova is transforming the fertility care experience.

Founder Aparna (Amy) Divaraniya, Ph.D., expressed her excitement about the funding round, stating, "This investment reaffirms Oova's mission to empower women and transform the fertility care landscape. With the support of our esteemed investors, we will continue to innovate and advance our technology to provide women and their care teams with the clearest steps towards conception."